Myfortic (Mycophenolic Acid)

Mycophenolic Acid inhibits the enzyme inosine monophosphate dehydrogenase, which is essential for the de novo synthesis of guanosine nucleotides. This blockade limits the proliferation of T‑ and B‑lymphocytes, the cells responsible for mounting an immune response against a transplanted organ, thereby reducing rejection risk.

The exact dose of Myfortic is individualized by the prescribing clinician based on factors such as the type of transplant, patient weight, renal function, concomitant immunosuppressants, and therapeutic drug monitoring results. No fixed regimen can be stated without a medical prescription.

Safety data for Myfortic in pregnancy and lactation are limited. Because the drug can cross the placenta and is excreted in breast milk, clinicians usually advise women of child‑bearing potential to discuss alternative immunosuppressive strategies or to weigh potential benefits against fetal risks before use.

To request Myfortic, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Myfortic (mycophenolic acid) offers a distinct mechanism by targeting nucleotide synthesis, whereas calcineurin inhibitors such as tacrolimus act on T‑cell activation pathways. Myfortic is often combined with a calcineurin inhibitor to achieve synergistic immunosuppression, and it may have a different side‑effect profile, particularly lower nephrotoxicity but higher gastrointestinal intolerance.

Myfortic should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in bathrooms or other humid environments.

Myfortic is taken orally, usually as whole tablets or capsules, with or without food as directed by the prescriber. Doses are typically spaced evenly throughout the day, and patients should follow the exact timing and any specific instructions regarding concomitant medications.

The most serious risks include severe infections (including opportunistic pathogens), progressive multifocal leukoencephalopathy (PML), and an increased incidence of certain malignancies such as post‑transplant lymphoproliferative disorder. Regular monitoring for signs of infection and malignancy is essential during therapy.

Myfortic is contraindicated in patients with known hypersensitivity to mycophenolic acid or any of its excipients. It should also be avoided in individuals with active, uncontrolled infections, severe bone‑marrow suppression, or in those who are pregnant without a clear clinical justification.